Literature DB >> 10735273

The genomic organization of human dystrobrevin.

H M Sadoulet-Puccio1, C A Feener, D J Schaid, S N Thibodeau, V V Michels, L M Kunkel.   

Abstract

Dystrophin-related and dystrophin-associated proteins (DAPs) are thought to play an important role in the stability and maintenance of the plasma membrane during muscle contraction and relaxation. Studies conducted on the electric organ of Torpedo californica have shown that some of the DAPs are also involved in the formation and maintenance of neuromuscular junctions (NMJs). In addition, dystrophin and several DAPs have been shown to be the primary genetic defect in a number of phenotypically similar muscular dystrophies. We previously reported the identification and characterization of human dystrobrevin, a protein which is unique in being both homologous to dystrophin and a dystrophin-associated protein. Here we describe the genomic organization of the human dystrobrevin gene. It is encoded by 23 exons spanning at least 180 kb of chromosome 18q12. Three different C-termini of dystrobrevin are generated by the mutually exclusive mRNA splicing of three exons. Two alternatively spliced exons (exons 11A and 12) are utilized exclusively in striated muscles. A comparison between the genomic organization of dystrophin and human dystrobrevin shows that the two genes have significant similarities in their genomic structure, implying an ancestral or evolutionary relationship. Based on intronic sequence, a primer set was designed to specifically amplify each exon of dystrobrevin to screen for mutations by SSCP in patients with neuromuscular diseases for which dystrobrevin could be a candidate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10735273     DOI: 10.1007/s100480050006

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  11 in total

1.  Desmuslin, an intermediate filament protein that interacts with alpha -dystrobrevin and desmin.

Authors:  Y Mizuno; T G Thompson; J R Guyon; H G Lidov; M Brosius; M Imamura; E Ozawa; S C Watkins; L M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Complete deletion of all alpha-dystrobrevin isoforms does not reveal new neuromuscular junction phenotype.

Authors:  Dongqing Wang; Bridget B Kelly; Douglas E Albrecht; Marvin E Adams; Stanley C Froehner; Guoping Feng
Journal:  Gene Expr       Date:  2007

3.  Dystrobrevin and dystrophin: an interaction through coiled-coil motifs.

Authors:  H M Sadoulet-Puccio; M Rajala; L M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

4.  Characterization of human alpha-dystrobrevin isoforms in HL-60 human promyelocytic leukemia cells undergoing granulocytic differentiation.

Authors:  Agné Kulyte; Ruta Navakauskiene; Grazina Treigyte; Arunas Gineitis; Tomas Bergman; Karl-Eric Magnusson
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

5.  Identification and functional analysis of human transcriptional promoters.

Authors:  Nathan D Trinklein; Shelley J Force Aldred; Alok J Saldanha; Richard M Myers
Journal:  Genome Res       Date:  2003-02       Impact factor: 9.043

Review 6.  Primary noncompaction of the ventricular myocardium from the morphogenetic standpoint.

Authors:  U Bartram; J Bauer; D Schranz
Journal:  Pediatr Cardiol       Date:  2007-07-12       Impact factor: 1.838

Review 7.  The role of α-dystrobrevin in striated muscle.

Authors:  Masayuki Nakamori; Masanori P Takahashi
Journal:  Int J Mol Sci       Date:  2011-03-04       Impact factor: 5.923

Review 8.  Dystrophins and dystrobrevins.

Authors:  R G Roberts
Journal:  Genome Biol       Date:  2001-04-05       Impact factor: 13.583

9.  Expression of synemin in the mouse spinal cord.

Authors:  Yuji Mizuno; Jeffrey R Guyon; Koichi Okamoto; Louis M Kunkel
Journal:  Muscle Nerve       Date:  2009-05       Impact factor: 3.217

10.  Beta-synemin expression in cardiotoxin-injected rat skeletal muscle.

Authors:  Yuji Mizuno; Jeffrey R Guyon; Akiko Ishii; Sachiko Hoshino; Norio Ohkoshi; Akira Tamaoka; Koichi Okamoto; Louis M Kunkel
Journal:  BMC Musculoskelet Disord       Date:  2007-05-10       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.